Day: May 26, 2023

Priority Review Granted withPrescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif., May 26, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for lifileucel for patients with advanced melanoma. The FDA granted lifileucel Priority Review and assigned November 25, 2023 as the target action date for a decision under the Prescription Drug User Fee Act (PDUFA). The FDA is not currently planning to hold...

GEORGETOWN, Cayman Islands, May 26, 2023 (GLOBE NEWSWIRE) — StoneCo Ltd. (Nasdaq: STNE; B3: STOC31) (“Stone” or the “Company”), announced key management changes today, including the promotion of Mateus Scherer Schwening to the role of Chief Financial Officer. Mr. Scherer steps into the role previously held by interim CFO Silvio Morais. The Company also announced the retirement of President Augusto Lins from full-time responsibilities, transitioning to a part-time senior advisory role. These changes will take effect on July 1, 2023. Since joining Stone in 2015, Mr. Scherer has contributed significantly to the Company in various finance roles, most recently serving as Vice President of Finance since April 2022. Additionally, he held a position on the Board of Directors from May 2021 through April 2022 and served on the Finance Committee. “We...

Scottsdale, AZ, May 26, 2023 (GLOBE NEWSWIRE) — Senior Connect Acquisition Corp. I (the “Company”) (Nasdaq: SNRH), announced today that, the board of directors of the Company has unanimously voted to accelerate the deadline by which the Company must complete an initial business combination to June 8, 2023. Therefore, the Company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (as amended on December 12, 2023, the “Amended Charter”). As a result, the Company intends to dissolve and liquidate in accordance with the provisions of the Amended Charter, effective as of the close of business on June 9, 2023, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering...

Toronto, Ontario and Nucla, Colorado , May 26, 2023 (GLOBE NEWSWIRE) — Western Uranium & Vanadium Corp. (CSE:WUC) (OTCQX:WSTRF) (“Western” or ”Company”) is pleased to announce that its Board of Directors has adopted a shareholder rights plan agreement (the “Plan”). While the Plan is effective immediately, its continuance is subject to Western obtaining shareholder approval at our annual general and special meeting (the “AGM”) to be held on June 29, 2023. The Plan was adopted to help ensure, to the extent possible, the fair treatment of shareholders in the event of any take-over bid, other acquisition of control, and/or “creeping” take-over bid for the Company without payment to all shareholders of an adequate control premium. A creeping takeover bid occurs where acquisition of a significant interest in the Company takes place...

Atlanta, GA, May 26, 2023 (GLOBE NEWSWIRE) — Logistics Innovation Technologies Corp. (NASDAQ: LITT) (the “Company”) today announced that its board of directors (the “Board”) has determined to redeem all of its outstanding shares of Class A common stock (the “Public Shares”), effective as of the close of business on June 15, 2023, because the Company will not consummate an initial business combination within the time period required by its amended and restated certificate of incorporation (the “COI”). Pursuant to the COI, if the Company does not consummate an initial business combination by June 15, 2023, the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in...

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today the presentation of a poster at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One-on-one meetings may be scheduled directly with Molecular Templates. The poster will highlight interim efficacy and safety data on MT-6402, MTEM’s ETB program designed to activate T-cells through direct cell-kill of immunosuppressive PD-L1+ immune cells. MT-6402 can also deliver and induce the presentation...